Disclosed are (i) compounds of formula I, or pharmaceutically acceptable salts thereof; and (ii) lipidoid nanoparticles comprising compound of formula I or pharmaceutically acceptable salts thereof, as well as their use as vehicles for drug delivery across the blood-brain barrier.

The invention relates to the use of a polyphosphate salt as procoagulant mediator agent in medical devices or pharmaceutical compositions and the respective polyphosphate-containing medical devices and pharmaceutical compositions. The invention further relates to a method for preparing an aqueous fibroin solution by use of a microwave treatment. The invention further relates to a fibroin-containing structure produced or obtainable by the preparation method of the invention. The invention further comprises subsequent process steps leading to solidified fibroin products and to the use of said products for medical treatment.

The invention relates to the use of a polyphosphate salt as procoagulant mediator agent in medical devices or pharmaceutical compositions and the respective polyphosphate-containing medical devices and pharmaceutical compositions. The invention further relates to a method for preparing an aqueous fibroin solution by use of a microwave treatment. The invention further relates to a fibroin-containing structure produced or obtainable by the preparation method of the invention. The invention further comprises subsequent process steps leading to solidified fibroin products and to the use of said products for medical treatment.

The present invention relates to octopromycin, which is a synthetic peptide having excellent antibacterial activity against Acinetobacter sp. bacteria, and an antibacterial composition comprising the octopromycin as an active ingredient. Octopromycin or a fragment thereof according to the present invention exhibits high inhibitory effects on the growth and biofilm formation of Acinetobacter baumannii, which is a multi-drug resistant bacterium causing nosocomial infection, in addition to being free of cytotoxicity, thus finding advantageous applications in treating and preventing the infection of Acinetobacter baumannii.

The invention is directed to compositions comprising mosquito (e.g., Aedes aegypti) salivary polypeptides and related methods for preventing and/or treating mosquito-borne viral infections such as infections caused by flaviviruses and alphaviruses. The flavivirus that is prevented or treated includes Zika virus, West Nile virus, Dengue virus, tick-borne encephalitis virus, and yellow fever virus.

The present disclosure is directed to antithrombotic nanoparticles and methods of treating necrotizing enterocolitis.

A nanoparticle (NP)-peptide conjugate provides efficient steric hindrance/blockage of cellular membrane potassium (K.sup.+) channels to mediate depolarization of cellular membrane potential.

This invention relates generally to compositions useful for the maintenance of calcium homeostasis. In particular, this invention is directed to apoaequorin-containing effervescent compositions useful in preventing and/or alleviating diseases or symptoms associated with calcium imbalance. Certain embodiments of the invention further contain active ingredients including at least one stimulant (e.g., caffeine) and/or vitamin D.

This invention relates generally to compositions useful for the maintenance of calcium homeostasis. In particular, this invention is directed to apoaequorin-containing effervescent compositions useful in preventing and/or alleviating diseases or symptoms associated with calcium imbalance. Certain embodiments of the invention further contain active ingredients including at least one stimulant (e.g., caffeine) and/or vitamin D.

The present disclosure relates to compositions capable of absorbing UVA and UVB light. In particle, the present disclosure relates to UV screening compositions comprising at least a portion of LITE-1 polypeptides which are capable of absorbing UV light (e.g., UV-A and/or UV-B light).